Joiners No Joiners Today Leavers No Leavers Today What’s cooking in the IPO kitchen? Arrow Exploration Corp. (AIM: AXL ; TSXV: AXL) , the oil and gas exploration and production company, has conditionally raised approximately £8.8m and is due to complete its dual listing on AIM on 25 Oct. Market cap c£13.1m. Devolver Digital to join AIM, an award-winning digital video games publisher and developer in the indie games space. Recently awarded indie 'Publisher of the Year 2021' by GamesIndustry.biz.
Companies: ZYT CIC DMTR GILD LMS MMAG PYC SMRT SBI
Joiners Made Tech Group (MTEC.L) has joined AIM, a provider of digital, data and technology services to the UK public sector. Founded in 2008 and now with a headcount of over 240 across four UK locations (London, Manchester, Bristol and Swansea), Made Tech provides services that enable central government, healthcare and local government organisations to digitally transform. The Company works directly with public sector clients to drive the digital transformation of citizen services, creating eff
Companies: 7DIG ADME GTC PYC SAVE WAND
Physiomics plc put out its FY numbers at 7am this morning. We have published research on this and a snapshot of the research is below and attached in full. Strong balance sheet and expanded technical/commercial team to drive multiple growth opportunities. The consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions has reported FY June 2021 results broadly in line with guidance. Total income (revenue and grant income) decrea
Companies: 1Spatial Plc (SPA:LON)Physiomics Plc (PYC:LON)
The consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions has reported FY June 2021 results broadly in line with guidance. Total income (revenue and grant income) decreased 13% to £730,899 (2020: £841,649), the third highest in the Company’s history despite a full year of the impact of Covid19 and the loss after taxation increased 235% to £215,827 (2020: £64,424). In cash terms however, the Company ended the year just £4k
Companies: Physiomics Plc
Joiners No joiners today. Leavers No leavers today. What’s cooking in the IPO kitchen? Peel Hunt, a UK mid and small-cap specialist investment bank, announces its intention to seek admission of its ordinary shares to trading on AIM. Admission is expected to take place on or around 29 September. In conjunction with a placing of Ordinary Shares the Company will be conducting an intermediaries offer. Oxford Nanopore Tech—expected intention to float on the LSE (Standard). The company behind a
Companies: DDDD CCS FUM HRN IIG LEX ORCP PYC SNT TAM
Joiners Caracal Gold (GCAT.L) (Formerly Papillon Holdings) has been readmitted to the Main Market with contemporaneous dual listing on the Frankfurt Stock Exchange. As part of the Readmission process, the Company has raised gross proceeds of approximately £5,493,885 completed in two rounds at a placing price of £0.01 per share, implying a market capitalisation of circa £14.5m on Readmission. The Company aims to build a position as an emerging East African focused gold producer with a clear path
Companies: BHL PSYC FUM ORCP PYC KETL TRR VLS VRCI
Dish of the day Bould Capital readmitted to AIM changing name to Cizzle Biotechnology Holdings (CIZ.L). Cizzle Biotechnology is in the early stages of developing a blood test for the early detection of a majority of the different forms of lung cancer. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of C1Z1 known as CIZ1B. C1Z1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted C1Z1B variant is hi
Companies: ASTO CNIC ETX GHE HUW MYX IOG PYC SRES VEL
Dish of the day Glantus Holdings GLAN.L, a provider of accounts payable automation and analytics solutions, has joined AIM. It is focusing on three product areas; Active AP Discovery, Intelligent AP Automation and Advanced AP Analytics, it utilises its internally developed data platform to offer an integrated solution for the finance function, accounts payable in particular. These solutions are offered to over 300 customers, more than 50 of which Glantus classifies as large enterprises. From 20
Companies: AIR ADV BBSN IES OMG PYC SWC ULS VCAP YCA
Dish of the day Catena Group completed a reverse takeover on AIM and renamed Insig AI (INSG.L) by acquiring the remaining shares of Insight Capital Partners. Insight, which is based in the UK, is a data science and machine learning solutions company that provides bespoke web-based applications, advanced analytical tools and modern technology infrastructure to make machine learning accessible to investment professionals. Insight has developed five products specifically aimed at accelerating an a
Companies: BEG CRCL ECP MIO ORPH PYC RUA STM
Joiners: Poolbeg Pharma (POLB.L)* a clinical stage infectious disease pharmaceutical company with a capital light clinical model has joined AIM. Funds raised as part of Admission will be used primarily to fund the clinical trial costs associated with the development of the Company’s POLB 001 asset as a treatment for severe influenza and to acquire and develop new portfolio assets. Raised £25m at 10p. Mkt Cap £50m. Oversubscribed fundraise which resulted in an increased raise from £20m to £25m d
Companies: CSFS ECR IDEA JADE NAPS SAR PYC THX
The consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions today announced that it had been awarded two further contracts by existing client Bicycle Therapeutics that it expects to be completed over the next six months. These projects relate to two of Bicycle's lead clinical assets and build on earlier work completed by Physiomics on these assets. This is the third announcement of contract awards this month. The firs
The provider of technology-based solutions to predict the effects of cancer treatment regimens for the biopharma industry today announced that its total income for the financial year ending 30 June 2021 is likely to be in the range of £700k-£800k and its loss after tax in the range of £170-200k. This is below market expectations and due to both COVID related project delays and to an increased focus on longer-term value-generating activities. The majority of Physiomics’ consulting work rela
Parsley Box, the direct to consumer provider of ready meals to the 60+ demographic, recently announced its AIM IPO plans. Parsley Box provides ready meals, which are not required to be stored in a fridge or freezer, have a shelf life of up to six months and are cooked in minutes. The company reported revenue of £24.4m for the financial year ended 31 December 2020 (unaudited). Deal details TBC and admission is expected to occur late March/ early April 2021. Caerus Mineral Resources, a London base
Companies: HUM IDOX BEM GHH PYC GTC SYM BEG SENS
Umuthi Healthcare (UHS.L) , the technology led healthcare business focused on the distribution of pharmaceuticals and the provision of medical facilities in remote areas has joined the main market (standard). No funds raised. Umuthi onboarded 2,000 clients during the previous financial year which represents a single digit fraction of the immediately available customers to its MedTech platform and have booked revenues as a result of these sales, ensuring tangible proof of concept. The bespoke p
Companies: CCS PYC FRAN MCL ABDP IUG AGL K3C KOO MDZ
The oncology consultancy using mathematical models and its Virtual Tumour™ technology to support the development of cancer treatment regimens and personalised medicine solutions, today announces its financial results for the six months ended 31 December 2020. Total income was up 12% to £363k. Operating losses of £132k were just £14k greater than those of the comparable prior period despite a significant increase in marketing activities. The Company finished the half with a strong balance sheet w
Research Tree provides access to ongoing research coverage, media content and regulatory news on Physiomics Plc. We currently have 63 research reports from 1 professional analysts.
Full-year results were in line with the trading update of 21 July, with revenues of £31m (-2%), reflecting the impact of COVID-19 on out-patient procedure rates, resulting in 14% and 24% declines in adjusted EBITDA and pre-tax profit, respectively. Lower than expected procedure growth rates and the decision to discontinue non-core (non-chlorine dioxide products) reduces forecast revenues by c.£3m to £33m in FY 2022. However, higher gross profit and tight control of costs (+6%) results in an unch
Companies: Tristel Plc
Recruitment resumed the Phase 2a trial of the lead programme hRPC in retinitis pigmentosa (RP) with the treatment of the first UK-patient in Oxford. The protocol gives greater infection control after the safety issue (a possible infection) in June. Five patients were treated up to mid-October and the remaining four could be treated by December 2021. By late March 2022, ReNeuron expects to give an interim update. The full data set should be available around mid-2022. This will enable regulatory d
Companies: ReNeuron Group plc
Joiners No Joiners Today. Leavers No Leavers Today. What’s cooking in the IPO kitchen? Devolver Digital to join AIM, an award-winning digital video games publisher and developer in the indie games space. Recently awarded indie 'Publisher of the Year 2021' by GamesIndustry.biz. Offer TBA. Due early Nov. Life Science REIT to join AIM raising up to £100m. This will be the first London listed real estate investment trust (REIT) focused on UK life science properties providing investors with exposure
Companies: SYS1 ARE SO4 SNG TMG TMT OHG IDE KIBO MRL
Companies: WAND SDX SEMP BMK LVCG MOS ACC
IXICO has announced that one of its clients has put an indefinite halt on a clinical trial for which the company was providing its artificial intelligence medical image analysis. The halt is the result of unexpected preclinical data. IXICO had expected the contract to deliver £0.8m of revenues in FY22E and it represented £3.3m of the £18.8m order book as of the close September 2021. While this news is disappointing, clearly the trial halt has no reflection on the capability of IXICO's technology
Companies: IXICO Plc
IXICO has provided an upgraded trading statement for FY21E following its previous update in August 2021. Revenues are now expected to be £9.2m (vs £8.7m previously), broadly in line with FY20A, which we see as a strong result given the pandemic and Huntington's Disease (HD) trials de-scope. EBITDA is expected to be materially ahead of FY20A's £1.3m, supported by strong Q4/21 trading, cost control and positive one-offs. The company has ended FY21 with a strong order book (£18.8m) and cash positio
CareTech is a specialist social care and educational services provider. This morning, the group has announced an update for the year to 30 September pointing to the fact that results will be in line with market expectations. The net debt position of £259m illustrates a further reduction since the end of H1 (31 March £263.1m) and implying a reduction to 2.7x adjusted EBITDA. During the year, seven new developments have opened, with a further eight properties purchased in H2. The group's freehold
Companies: CareTech Holdings PLC
H1 EBITDA declined by 45% YoY, albeit this was slightly better than we had anticipated after the pre-close update in August. The beat was cost related (efficiencies/savings). There was a significant gross margin drag though and, while transitory in nature and diminishing in H2, this means further savings need to be realised to hit full year forecasts. This is our view and we retain a good level of confidence in next year’s forecasts. Having de-rated, valuation looks very undemanding now on just
Companies: Venture Life Group Plc
SkinBioTherapeutics has announced it will launch its lead commercial product, AxisBiotix-Ps on World Psoriasis Day, 29 October 2021. To support the launch, the company has begun to receive, and store finished product in the Netherlands (close to its manufacturing partner) ahead of initial launches in the UK and US. Clearly the launch of its first product is a significant step for SkinBioTherapeutics, marking the transition from development company to commercial operation. We are encouraged by th
Companies: SkinBioTherapeutics Plc
Synairgen reported interim results to 30 June in which the adjusted net loss was £32.8m with period-end cash of £46.2m. Substantial pre-commercial progress and manufacturing activities have made in the half, although slower country approvals for trial sites will result in Phase III data readout slipping into Q1 2022. With increasing evidence of the need for a broad-spectrum antiviral delivered to the lungs and recognition that vaccines don’t provide complete protection against hospitalisations d
Companies: Synairgen plc
*A corporate client of Hybridan LLP Joiners No joiners today. Leavers Conduity Capital has left AIM. What’s cooking in the IPO kitchen? Softline the global solutions and services provider in digital transformation and cybersecurity, with its headquarters in London, is considering proceeding with a potential initial public offering of global depositary receipts representing its ordinary shares. The Company is considering applying for admission of the GDRs to the standard listing segm
Companies: SEN SEMP DNORD DNORD FAB MAST SAR CZA MRL
Joiners No Joiners Today. Leavers Cambria Autos has left the AIM following a takeover. What’s cooking in the IPO kitchen? Light Science Tech Holdings, the controlled environment agriculture technology and contract electronics manufacturing Group to join AIM. Raising £5m. Expected mkt cap £17.4m. Due 15 Oct. Harmony Energy Income Trust to join the Specialist Fund Segment of the Main Market raising up to £230m. The Company's investment objective is to provide investors with an attractive and susta
Companies: VRS ORPH SNG MRL EBQ AVG
Hikma’s H1 20 top-line acceleration was driven by COVID-19-related demand in Injectables and Generics and the economic recovery in Algeria propelled growth in the Branded segment. Combined with a favourable product-mix, the operating margin was up 1.5ppt. In the near term, new launches across segments should provide some respite against the ongoing pricing pressure. Given the company’s thin R&D pipeline and a robust balance sheet, M&A (probably in the biosimilars space) seems on the cards.
Companies: Hikma Pharmaceuticals Plc
Samarkand Group Limited, the cross-border eCommerce technology and retail group opening up the world's largest market for brands and retailers, intends to IPO on the Apex Segment Aquis Stock Exchange Growth Market. Admission is targeted for March 2021. Cellular Goods a UK-based provider of premium consumer products based on biosynthetic cannabinoids announced its intention to join the main market (standard) this spring. Target valuation £20m raising c. £8m “to finalise the development and launch
Companies: SYM ABDX NBI BPM TND BRCK PRES ENET CDGP
Today’s prelims are in line with management’s expectations with losses before tax in the period of £30.3m (vs. £29.4m prior year). Post-merger, 4D pharma is clearly a different beast with access to the largest global capital market for Pharma/Biotech, and supported by £25.2m (net) proceeds from corporate activity. The company has cash runway until Q2 2022 and is well placed to successfully execute its clinical development strategy with multiple shots on goal. Primary focus is on MRx0518 with two
Companies: 4d Pharma PLC
